PBMNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBMWW
PSYENCE BIOMEDICAL LTD.
Financials through Q2 FY2026, quarter ended Sep 30, 2025Last filing: 20-F on Jun 22, 2026
$4.12−0.10 (-2.37%)
Close on Oct 19, 2026
Market cap
$6.10M
P/E (TTM)
0.8
Dividend yield
–
Psyence Biomedical statistics
Financials through Sep 30, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
Measure
Psyence Biomedical
Industry median
Market Cap
$9.45M
$166.30M
Enterprise Value
$2.30M
$87.12M
PE Ratio
0.79
19.67
Income (trailing twelve months)
Measure
Psyence Biomedical
Industry median
Pretax Income
-$3.66M
-$14.72M
EPS (Diluted)
$5.24
-$0.83
Balance sheet
Measure
Psyence Biomedical
Industry median
Cash & Short-Term Investments
$7.15M
$62.64M
Net Cash (Debt)
$7.15M
$15.77M
Net Cash Per Share
$3.12
$0.66
Cash flow (trailing twelve months)
Measure
Psyence Biomedical
Industry median
Operating Cash Flow
-$3.73M
-$12.39M
Capital Expenditures
-$9.88K
-$1.07M
Free Cash Flow
-$3.74M
-$20.34M
FCF Per Share
-$1.63
-$0.42
Efficiency
Measure
Psyence Biomedical
Industry median
Employee Count
12
74
Dividends and yields
Measure
Psyence Biomedical
Industry median
FCF Yield
-39.6%
-9.02%
Buyback Yield
-18.4%
-0.73%
Shareholder Yield
-18.4%
0.00%
Shares
Measure
Psyence Biomedical
Industry median
Shares Outstanding
2,293,280
58,139,000
Shares Change (YoY)
1670.6%
11.1%
Scores
Measure
Psyence Biomedical
Industry median
Altman Z-Score
-0.38
-0.27
Calculated by StockData from Psyence Biomedical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.